• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Ishares S And P S>iShares S&P S/T Natnl AMT-Free Muni Bd

iShares S&P S/T Natnl AMT-Free Muni Bd

iShares National Muni Bond MUB 4 Star

Last Price$108.30Day Change (%)0.13%
Open Price$108.27Day Change ($)0.14
Day Range108.19–108.3252-Week Range106.30–115.19

As of Sat 2/17/2017 8:59:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. $10.96 Billion Concentrating Solar Power Market 2017 by Technology, Components, End-User and Region - Global Forecast to 2021 - Research and Markets

    $10.96 Billion Concentrating Solar Power Market 2017 by Technology, Components, End-User and Region - Global Forecast to 2021 - Research and Markets

  2. Pixium Vision Announces First Implantation and Activation of IRIS® II in Spain

    Pixium Vision Announces First Implantation and Activation of IRIS® II in Spain

  3. TriLinc Global Impact Fund Surpasses $500 Million in Investments in Africa, Latin America, and Southeast Asia

    TriLinc Global Impact Fund Surpasses $500 Million in Investments in Africa, Latin America, and Southeast Asia

  4. MSCI Triples the Number of its Private Real Estate Indexes Available on Global Intel PLUS

    MSCI Triples the Number of its Private Real Estate Indexes Available on Global Intel PLUS

  5. H.I.G. Capital Acquires Assets of Xtera Communications, Inc.

    H.I.G. Capital Acquires Assets of Xtera Communications, Inc.

  6. UPDATE: Why you should think like a team when saving for your retirement

    UPDATE: Why you should think like a team when saving for your retirement

  7. ABB Wins $70 Million in Equipment Orders to Expand European Rail Fleets

    ABB Wins $70 Million in Equipment Orders to Expand European Rail Fleets

  8. BDO USA, LLP and Indiggo Form Strategic Alliance to Market Indiggo Leadership Technology Platform

    BDO USA, LLP and Indiggo Form Strategic Alliance to Market Indiggo Leadership Technology Platform

  9. Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

    Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

  10. Mercialys: Strong Increase in 2016 Results

    Mercialys: Strong Increase in 2016 Results

12345

©2017 Morningstar Advisor. All right reserved.